Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

Japjec M, Horvat Pavlov K, Petrovic A, Seiwerth S, Sikiric P, et al. · Biomedicines

Both routes restored macroscopic, biomechanical and functional measures and normalised eNOS and COX-2 mRNA, oxidative stress and NO levels; inflammatory infiltrate was gone and oriented junction tissue present by days 28–42, with the defect closing rather than persisting.

Population

Rats with the quadriceps tendon dissected from the quadriceps muscle — a junction defect that does not heal spontaneously

Intervention

BPC 157 10 µg/kg or 10 ng/kg i.p., or per-orally in drinking water (0.16 µg/mL or 0.16 ng/mL), to day 7, 14, 28 or 42

Comparator

Untreated junction defect

Limitations

Originating network; the drinking-water arm makes ingested dose approximate rather than controlled.